Phase I Study of Hemay102 in Patients With Advanced Solid Tumors
Status:
Recruiting
Trial end date:
2021-12-31
Target enrollment:
Participant gender:
Summary
This trial was a single-center, open-label, dose-increasing Phase I clinical study with
subjects enrolled in patients with advanced solid tumors who failed standard treatment or who
were unable to receive effective treatment. The trial is divided into two stages: dose
escalation and dose extension.